Long-acting contraception in adolescents and young women with type 1 and type 2 diabetes
Author
dc.contributor.author
Salinas Quero, Abril
Author
dc.contributor.author
Merino Osorio, Paulina
Author
dc.contributor.author
Giraudo, Franco
Author
dc.contributor.author
Codner Dujovne, Ethel
Admission date
dc.date.accessioned
2020-10-15T23:22:17Z
Available date
dc.date.available
2020-10-15T23:22:17Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Pediatr Diabetes. 2020;1–9.
es_ES
Identifier
dc.identifier.other
10.1111/pedi.13069
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/177176
Abstract
dc.description.abstract
Adolescent pregnancy is a major public health problem worldwide. Adolescents living with diabetes are not aware of the risks of unplanned pregnancy and the high rate of fetal and maternal complications when gestation occurs in women with significant hyperglycemia. These data highlight the significance of pregnancy prevention in young women with diabetes. Long-acting reversible contraceptives (LARCs), which include subdermal progestin implants and hormonal and nonhormonal intrauterine devices (IUDs), have been recommended by the American College of Obstetricians Gynecologists and the American Academy of Pediatrics as a first-line contraceptive option for adolescents and young women. This article reviews LARC options for adolescents and young women with type 1 (T1D) and type 2 (T2D) diabetes as well as the possible complications and side effects.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1170895